200 related articles for article (PubMed ID: 21046073)
1. Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A.
Kreimeyer I; Euler F; Marckscheffel A; Tatge H; Pich A; Olling A; Schwarz J; Just I; Gerhard R
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):253-62. PubMed ID: 21046073
[TBL] [Abstract][Full Text] [Related]
2. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity.
Egerer M; Giesemann T; Jank T; Satchell KJ; Aktories K
J Biol Chem; 2007 Aug; 282(35):25314-21. PubMed ID: 17591770
[TBL] [Abstract][Full Text] [Related]
3. Autocatalytic processing of Clostridium difficile toxin B. Binding of inositol hexakisphosphate.
Egerer M; Giesemann T; Herrmann C; Aktories K
J Biol Chem; 2009 Feb; 284(6):3389-95. PubMed ID: 19047051
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol.
Li S; Shi L; Yang Z; Feng H
Pathog Dis; 2013 Feb; 67(1):11-8. PubMed ID: 23620115
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
6. Serine-71 phosphorylation of Rac1/Cdc42 diminishes the pathogenic effect of Clostridium difficile toxin A.
Schoentaube J; Olling A; Tatge H; Just I; Gerhard R
Cell Microbiol; 2009 Dec; 11(12):1816-26. PubMed ID: 19709124
[TBL] [Abstract][Full Text] [Related]
7. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
8. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
[TBL] [Abstract][Full Text] [Related]
9. Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells.
Gerhard R; Nottrott S; Schoentaube J; Tatge H; Olling A; Just I
J Med Microbiol; 2008 Jun; 57(Pt 6):765-770. PubMed ID: 18480335
[TBL] [Abstract][Full Text] [Related]
10. Substrate specificity of clostridial glucosylating toxins and their function on colonocytes analyzed by proteomics techniques.
Zeiser J; Gerhard R; Just I; Pich A
J Proteome Res; 2013 Apr; 12(4):1604-18. PubMed ID: 23387933
[TBL] [Abstract][Full Text] [Related]
11. The combined repetitive oligopeptides of clostridium difficile toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation.
Olling A; Hüls C; Goy S; Müller M; Krooss S; Rudolf I; Tatge H; Gerhard R
Toxins (Basel); 2014 Jul; 6(7):2162-76. PubMed ID: 25054784
[TBL] [Abstract][Full Text] [Related]
12. Human alpha-defensins inhibit Clostridium difficile toxin B.
Giesemann T; Guttenberg G; Aktories K
Gastroenterology; 2008 Jun; 134(7):2049-58. PubMed ID: 18435932
[TBL] [Abstract][Full Text] [Related]
13. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A.
Olling A; Goy S; Hoffmann F; Tatge H; Just I; Gerhard R
PLoS One; 2011 Mar; 6(3):e17623. PubMed ID: 21445253
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning, overexpression in Escherichia coli, and purification of 6x his-tagged C-terminal domain of Clostridium difficile toxins A and B.
Letourneur O; Ottone S; Delauzun V; Bastide MC; Foussadier A
Protein Expr Purif; 2003 Oct; 31(2):276-85. PubMed ID: 14550648
[TBL] [Abstract][Full Text] [Related]
15. Difference in F-actin depolymerization induced by toxin B from the Clostridium difficile strain VPI 10463 and toxin B from the variant Clostridium difficile serotype F strain 1470.
May M; Wang T; Müller M; Genth H
Toxins (Basel); 2013 Jan; 5(1):106-19. PubMed ID: 23344455
[TBL] [Abstract][Full Text] [Related]
16. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.
D'Auria KM; Bloom MJ; Reyes Y; Gray MC; van Opstal EJ; Papin JA; Hewlett EL
BMC Microbiol; 2015 Feb; 15(1):7. PubMed ID: 25648517
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.
Gerhard R; Queisser S; Tatge H; Meyer G; Dittrich-Breiholz O; Kracht M; Feng H; Just I
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):285-95. PubMed ID: 21267712
[TBL] [Abstract][Full Text] [Related]
18. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
Chen B; Liu Z; Perry K; Jin R
Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
[TBL] [Abstract][Full Text] [Related]
19. Difference in the biological effects of Clostridium difficile toxin B in proliferating and non-proliferating cells.
Lica M; Schulz F; Schelle I; May M; Just I; Genth H
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):275-83. PubMed ID: 21212934
[TBL] [Abstract][Full Text] [Related]
20. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
